Thyroid Cancer Subtypes Decoded From Molecular Drivers to Targeted Cures
A comprehensive review maps the distinct molecular mechanisms and emerging therapies across all four thyroid cancer subtypes.
Summary
Thyroid cancer is the seventh most common malignancy worldwide, with over 821,000 new cases reported in 2022. This review covers the four major subtypes — papillary (PTC), follicular (FTC), medullary (MTC), and anaplastic (ATC) — detailing their distinct molecular drivers, diagnostic biomarkers, and therapeutic strategies. PTC, accounting for 85–90% of cases, is largely driven by the BRAF V600E mutation activating MAPK signaling. FTC is characterized by RAS mutations and PI3K/AKT activation. MTC involves RET proto-oncogene mutations with immunotherapy potential, while ATC carries TERT promoter and TP53 mutations conferring extreme aggressiveness. Targeted therapies — vemurafenib for PTC, sorafenib for FTC, vandetanib for MTC, and berberine-doxorubicin for ATC — represent the current therapeutic backbone, with metabolic and RNA-based interventions emerging as promising adjuncts.
Detailed Summary
Thyroid cancer has become a global health concern, ranking as the seventh most common malignancy worldwide in 2022 with more than 821,000 reported cases. The disease disproportionately affects women and individuals with genetic predispositions or family history. This review systematically examines the molecular underpinnings, diagnostic innovations, and therapeutic advances across the four principal histological subtypes: PTC (85–90% of cases), FTC (~10%), MTC (1–5%), and ATC (1–2%). Each subtype harbors distinct molecular signatures that demand subtype-specific management approaches rather than a one-size-fits-all strategy.
PTC's molecular landscape is dominated by the BRAF V600E mutation, detectable by immunohistochemistry with a pooled sensitivity of 96.8% (95% CI: 94.1–98.3%). This mutation constitutively activates the MAPK/MEK/ERK cascade, upregulates hexokinase-2, and promotes metabolic reprogramming through aerobic glycolysis. Non-coding RNAs play equally important roles: lncRNA MALAT1 and hsa-miR-1270 are upregulated in PTC cell lines such as TPC-1 and K1, while tumor-suppressive factors like FAM111B constrain glycolytic flux, and SLC6A15 inhibits migration and invasion via ICAM-1 signaling. The PI3K/AKT/mTOR and Wnt/β-catenin pathways also emerge as druggable axes in PTC.
FTC is characterized by RAS mutations that activate both MAPK and PI3K/AKT pathways, enabling enhanced lipid metabolism and greater invasiveness compared to PTC, with higher rates of distant metastasis to lungs and bone. Key regulators highlighted in this review include METTL16, which interacts with stearoyl-CoA desaturase 1 to activate lipid metabolism pathways, and sclerostin domain-containing protein 1 (SOSTDC1), which modulates FTC progression. MTC, originating from calcitonin-secreting parafollicular C cells, is strongly linked to gain-of-function RET proto-oncogene mutations with notable hereditary predisposition. A critical finding is the involvement of the PD-1/PD-L1 immune checkpoint pathway in MTC, opening a credible immunotherapy avenue, alongside novel drug delivery systems using micelle-encapsulated AB3.
ATC is the most lethal subtype, defined by recurrent TERT promoter and TP53 mutations, activation of cancer-associated fibroblasts through CREB3L1 signaling, and HN1-stathmin 1-mediated invasiveness. Diagnostically, the review highlights an expanding biomarker toolkit: serum stanniocalcin-1 and miR-26b-5p signatures for PTC and MTC detection, radiomics-based differentiation of ATC from other subtypes, and optical imaging for precision intraoperative diagnosis. These tools are positioned to complement or eventually reduce dependence on invasive fine-needle aspiration biopsy.
Therapeutically, the review establishes a clear subtype-to-drug framework: vemurafenib targets BRAF/MEK in PTC, sorafenib acts as a multikinase inhibitor in FTC, vandetanib blocks RET signaling in MTC, and berberine-doxorubicin combinations are being explored to overcome chemoresistance in ATC. Metabolic interventions, particularly metformin for glucose modulation in PTC, add another dimension to combination therapy. The authors emphasize that understanding subtype-specific molecular architecture is essential for translating these mechanistic insights into improved clinical outcomes, and they call for further mechanistic and clinical studies particularly for the less-studied FTC, MTC, and ATC subtypes.
Key Findings
- PTC accounts for 85–90% of all thyroid cancer cases; BRAF V600E mutation is detectable by IHC with 96.8% pooled sensitivity (95% CI: 94.1–98.3%)
- Thyroid cancer was the seventh most common malignancy globally in 2022, with over 821,000 reported cases, with higher incidence in women and those with genetic predispositions
- METTL16 activates lipid metabolism in FTC by interacting with stearoyl-CoA desaturase 1 and inhibits PTC progression via interaction with YTHDC2
- ATC, representing only 1–2% of thyroid cancers, carries recurrent TERT promoter and TP53 mutations and activates cancer-associated fibroblasts through CREB3L1 signaling, driving extreme aggressiveness
- MTC is associated with RET proto-oncogene gain-of-function mutations and PD-1/PD-L1 pathway involvement, identifying credible immunotherapy targets
- lncRNA MALAT1 and hsa-miR-1270 are significantly upregulated in PTC cell lines (TPC-1, K1) and human PTC tumors, correlating with larger tumor size and worse prognosis
- Berberine-doxorubicin combination therapy shows preclinical potential in overcoming chemoresistance in ATC, and micelle-encapsulated AB3 demonstrates translational promise for MTC drug delivery
Methodology
This is a narrative review article synthesizing published literature on thyroid cancer molecular mechanisms, diagnostics, and therapies across four histological subtypes (PTC, FTC, MTC, ATC). The authors performed a comprehensive literature search drawing on PubMed-indexed studies and bioinformatics analyses of miRNA-mRNA regulatory networks. No original patient data, sample sizes, randomization, or statistical analyses were generated by the authors themselves; all quantitative figures cited derive from referenced primary studies. The review is organized by subtype, with each section covering molecular mechanisms, signaling pathways, diagnostic approaches, and therapeutic strategies.
Study Limitations
As a narrative rather than systematic review with meta-analysis, the paper is subject to selection bias in the literature included and does not provide pooled effect sizes across studies. The majority of mechanistic findings cited derive from in vitro cell line experiments and animal models, limiting direct clinical applicability. The authors declare no conflicts of interest, but the review is funded by several Chinese provincial and institutional grants, and does not include a formal PRISMA or GRADE assessment of evidence quality.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: